Andy Chai
Analyst at William Blair
Replay available
Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call
Cardiff Oncology, Inc. (NASDAQ: CRDF) Q3 2023 earnings conference call, held 2023-11-02. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Mark Erlander
Chief Executive Officer
Joe Catanzaro
Analyst at Piper Sandler
Mark Fram
Analyst at TD Cowan
Jamie Levine
Chief Financial Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Cardiff Oncology, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.109 -- 00:00:04.351 Welcome to the Cardiff Oncology Third Quarter 2023 00:00:04.351 -- 00:00:07.972 Financial Results and Corporate Update Conference Call. 00:00:07.972 -- 00:00:11.413 At this time, all participants are in a listen-only mode. 00:00:11.413 -- 00:00:15.935 Following management's prepared remarks, we will hold a Q&A session. 00:00:15.935 -- 00:00:21.256 To ensure that we have ample time to address everyone's questions during the Q&A session, 00:00:21.256 -- 00:00:26.604 we would ask for a limit of one question and one follow-up question per person. 00:00:26.604 -- 00:00:32.108 To ask a question at that time, please press star followed by 11 on your touchtone 00:00:32.108 -- 00:00:33.949 phone. 00:00:33.949 -- 00:00:38.312 As a reminder, this call is being recorded today, November 2nd, 2023. 00:00:38.312 -- 00:00:43.515 I would now like to turn the conference call over to Kiki Patel of Gil 00:00:43.515 -- 00:00:45.316 Martin Group. Please go ahead. 00:00:45.316 -- 00:00:47.258 Thank 00:00:47.258 -- 00:00:52.101 you, Operator. Joining us on the call today from Cardiac Oncology are Chief Executive 00:00:52.101 -- 00:00:56.189 Officer Mark Erlander and Chief Financial Officer Jamie Levine. 00:00:56.189 -- 00:00:59.891 During this conference call, management will make forward-looking statements, including, 00:00:59.891 -- 00:01:04.473 without limitation, statements related to guidance, results, and the timing of data readout 00:01:04.473 -- 00:01:08.956 for unadvantaged clinical trials. These forward-looking statements are based on the company's 00:01:08.956 -- 00:01:14.059 current expectations and inherently involve significant risks and uncertainties. 00:01:14.059 -- 00:01:18.561 Our actual results and the timing of events could differ mate...